Pharmaceuticals, Biotechnology and Life Sciences
Pharmaceutical companies have started to embrace a more collaborative way of working as part of a movement to help overcome some of the challenges the industry is facing. Expiring patents and a tight regulatory environment are just some of the issues that are hoped to be resolved through forming partnerships across the industry, and even with competitors.
mRNA-1273 delivered from Company’s cGMP facility in 42 days from sequence selection CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical
AFFiRiS AG, a clinical-stage biopharmaceutical company developing novel disease-modifying specific active immunotherapies (SAITs) for patients with neurodegenerative diseases, will proceed with the preparations for the planned phase 2 study and confirms its intended initiation in the US and Europe in the second half of 2020.
